Xbrane Biopharma says it is now in a position to follow through on its planned EU and US filings for its Xlucane (ranibizumab) biosimilar after reporting positive results from Phase III trials for the rival to Lucentis.
Xbrane Data Sets Up EU And US Ranibizumab Filings
Filing Dates Confirmed For Xlucane Biosimilar Of Lucentis After Phase III Results
Hot on the heels of Samsung Bioepis receiving an EMA endorsement for its Byooviz version, Xbrane Biopharma has laid out plans for its own ranibizumab biosimilar, Xlucane, to be filed in both the EU and the US following positive Phase III results.
